Table 4 ILD associated with neo/adjuvant AC or (F)EC chemotherapy in early breast cancer
Chemotherapy | Author | Year | ILD | Cause |
|---|---|---|---|---|
Clinical trials | Â | Â | Â | Â |
AC | Fisher B et al. [3] | 1990 | NA | Â |
EC | Fisher B et al. [4] | 2001 | NA | Â |
AC→T, ddAC→T | Citron ML et al. [11] | 2003 | NA |  |
ddFEC | Dang CT et al. [12] | 2004 | 9% | Â |
AC→T vs →TH | Romond EH et al. [13] | 2005 | 0% vs 0.4%, 0.6% |  |
FEC | Venturini M et al. [14] | 2005 | 0% | Â |
ddFEC | Venturini M et al. [14] | 2005 | < 1% | Â |
AC | Jones SE et al. [5] | 2006 | NA | Â |
AC→T | Sparano JA et al. [6] | 2008 | < 0.5% |  |
ddEC→T | Dang C et al. [15] | 2008 | 0% |  |
EC→T vs EC→TH | Shimizu et al. [16] | 2010 | NA |  |
T→FEC | Gonzalez-Angulo AM et al. [17] | 2014 | 0% |  |
AC→T vs →TH | Waks AG et al. [18] | 2015 | 0% vs 0% |  |
ddAC→T vs →TH | Waks AG et al. [18] | 2015 | 0% vs 0.6% | PCP |
dd(F)EC→T, (F)EC→T | Del Mastro L et al. [19] | 2015 | NA |  |
ddEC→D, FEC | Foukakis T et al. [20] | 2016 | NA |  |
(F)AC, (F)EC→TH, DH vs (F)AC, (F)EC→THP or DHP | von Minckwitz G et al. [21] | 2017 | NA |  |
AC, EC→DC'H vs AC, EC→DC'HP | von Minckwitz G et al. [21] | 2017 | NA |  |
ddAC, ddEC→T | Takabatake D et al. [22] | 2018 | NA |  |
ddEC→Next treatment | Morita S et al. [23] | 2018 | 3.9% | PCP |
nab-PTX→FEC | Kin T et al. [24] | 2020 | NA |  |
Case reports | Â | Â | Â | Â |
ddAC | Tolaney SM et al. [25] | 2006 | 1 case | PCP |
dd (detailed regimen, not mentioned) | Tolaney SM et al. [25] | 2006 | 1 case | PCP |
FEC→T | Kawajiri H et al. [26] | 2013 | 5 cases |  |
FEC | Shinohara A et al. [27] | 2013 | 1 case | PCP |
ddAC→T | Bielopolsky D et al. [28] | 2017 | 3 cases |  |
EC→H | Sugaya A et al. [29] | 2017 | 1 case |  |
ddAC | Khoo C et al. [30] | 2019 | 1 case | PCP |